Matthew Meriggioli to Immunosuppressive Agents
This is a "connection" page, showing publications Matthew Meriggioli has written about Immunosuppressive Agents.
Connection Strength
0.753
-
Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003 Nov 25; 61(10):1438-40.
Score: 0.203
-
Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci. 2003 Sep; 998:494-9.
Score: 0.200
-
Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve. 2000 Aug; 23(8):1287-9.
Score: 0.161
-
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009 May; 8(5):475-90.
Score: 0.074
-
Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006 Apr 25; 66(8):1245-7.
Score: 0.060
-
Myasthenia gravis. Clin Neuropharmacol. 2000 Nov-Dec; 23(6):291-5.
Score: 0.041
-
Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004 Dec 28; 63(12):2390-2.
Score: 0.014